Everton Rowe
Impact in
-
- Diabetes Treatment and Management
- Diabetes Management and Research
- Pharmacology top 1%
- Pharmacology and Obesity Treatment
Papers in
- Oncology 9
- CAR-T cell therapy research 9
-
- Multiple Myeloma Research and Treatments 7
- Chronic Myeloid Leukemia Treatments 2
- Co-authors
- Ken Fujioka (3 shared papers)Carl M. Mendel (3 shared papers)Samuel Weinstein (3 shared papers)Bertrand Cariou (2 shared papers)J. Hans DeVries (1 shared paper)Mads Axelsen (1 shared paper)Milivoj Piletič (2 shared papers)Vanita R. Aroda (2 shared papers)
- Journals
- Blood (6 papers)Transplantation and Cellular Therapy (3 papers)HemaSphere (2 papers)Journal of Human Hypertension (2 papers)Canadian Journal of Diabetes (1 paper)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Everton Rowe
25 papers receiving 1.2k citations
Everton Rowe's Hit Papers
Peers
Comparison fields: 5 of 83
- Endocrinology, Diabetes and Metabolism 659
- Pharmacology 532
- Physiology 249
- Endocrine and Autonomic Systems 49
- Pharmacy 24
Countries citing papers authored by Everton Rowe
This map shows the geographic impact of Everton Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Everton Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Everton Rowe more than expected).
Fields of papers citing papers by Everton Rowe
This network shows the impact of papers produced by Everton Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Everton Rowe. The network helps show where Everton Rowe may publish in the future.
Co-authors
The 25 scholars most cited alongside Everton Rowe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial Hit paper breakdown → | 2017 | 351 |
| 2 | 2000 | 195 | |
| 3 | 2000 | 188 | |
| 4 | 2017 | 133 | |
| 5 | 2002 | 80 | |
| 6 | 2001 | 77 | |
| 7 | 2002 | 52 | |
| 8 | 2005 | 50 | |
| 9 | 2020 | 25 | |
| 10 | 2020 | 25 | |
| 11 | 2020 | 15 | |
| 12 | 2022 | 14 | |
| 13 | 1999 | 13 | |
| 14 | 2015 | 11 | |
| 15 | 2014 | 10 | |
| 16 | 2021 | 8 | |
| 17 | 2010 | 8 | |
| 18 | 2021 | 5 | |
| 19 | 2021 | 4 | |
| 20 | 2022 | 3 |
About Everton Rowe
Everton Rowe is a scholar working on Oncology, Hematology, Molecular Biology, Pharmacology and Endocrinology, Diabetes and Metabolism, having authored 25 papers that have together received 1.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (9 papers), Multiple Myeloma Research and Treatments (7 papers), Pharmacology and Obesity Treatment (5 papers), Protein Degradation and Inhibitors (4 papers), Diabetes Treatment and Management (3 papers), Chronic Myeloid Leukemia Treatments (2 papers), Hormonal and reproductive studies (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (659 citations), Pharmacology (532 citations), Physiology (249 citations), Endocrine and Autonomic Systems (49 citations) and Pharmacy (24 citations). Everton Rowe has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Ken Fujioka, Carl M. Mendel, Samuel Weinstein, Bertrand Cariou, J. Hans DeVries, Mads Axelsen, Milivoj Piletič, Vanita R. Aroda, Stephen C. Bain and Ludger Rose. Their work appears in journals such as Blood, Transplantation and Cellular Therapy, HemaSphere, Journal of Human Hypertension and Canadian Journal of Diabetes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.